Remdesivir waa dawo ka hortag fayrus ah oo bar-tilmaameedsada fayrasyo ​​kala duwan. Waxaa asal ahaan loo sameeyay toban sano ka hor si loogu daweeyo cagaarshow C iyo fayras hargab u eg oo la yiraahdo fayraska syncytial breath (RSV). Remdesivir ma ahayn daaweyn wax ku ool ah labada cudurba. Laakiin waxay muujisay ballanqaad ka dhan ah fayrasyada kale.

Cilmi-baarayaashu waxay tijaabiyeen remdesivir tijaabooyin caafimaad intii uu socday cudurka Ebola. Daawooyinka kale ee baaritaanka ayaa si fiican u shaqeeyay, laakiin waxaa la muujiyay inay badbaado u tahay bukaanada. Daraasado lagu sameeyay unugyada iyo xayawaanka ayaa soo jeediyay in remdesivir uu wax ku ool u yahay fayrasyada qoyska coronavirus, sida Bariga Dhexe ee neefsashada (MERS) iyo Syndrome Ba'an oo Ba'an oo Neefsashada ah (SARS).

Remdesivir wuxuu u shaqeeyaa isagoo joojiya soo saarista fayraska. Coronaviruses waxay leeyihiin genomes ka samaysan ribonucleic acid (RNA). Remdesivir wuxuu farageliyaa mid ka mid ah enzymes-yada muhiimka ah ee uu fayrasku u baahan yahay inuu ku soo celiyo RNA. Tani waxay ka hortagtaa inuu fayrasku tamo.

Cilmi baadhayaashu waxay bilaabeen tijaabo la kala soocay, oo la xakameeyey oo ka hortagga fayraska bishii Febraayo 2020 si ay u tijaabiyaan in remdesivir loo isticmaali karo daawaynta SARS-CoV-2, coronavirus-ka sababa COVID-19. Ilaa Abriil,natiijooyinka horeayaa tilmaamay in remdesivir ay dardargelisay soo kabashada bukaannada isbitaallada la dhigay ee qaba COVID-19 daran. Waxay noqotay dawadii ugu horreysay ee oggolaansho ka hesha Maamulka Cuntada iyo Dawooyinka ee Maraykanka (FDA) si loogu daweeyo dadka cusbitaalka la dhigay COVID-19.

Cilmi baadhayaashu hadda waxay soo gabagabeeyeen tijaabada, oo loo yaqaan tijaabinta daawaynta COVID-19 Adaptive COVID-19 (ACTT-1). Daraasada waxaa maalgeliyay Machadka Qaranka ee Xasaasiyadda iyo Cudurada Faafa (NIAID). Warbixinta ugu dambeysa ayaa ka soo baxdayWargeyska Caafimaadka ee New EnglandOktoobar 8, 2020.